{"DataElement":{"publicId":"5979442","version":"1","preferredName":"Invasive Breast Carcinoma Nuclear Pleomorphism Nottingham Histologic Score Outcome","preferredDefinition":"Results of the Nottingham histologic score for nuclei size and shape in a breast specimen.","longName":"IBC_NUPL_NOTSC_OUTCM","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"5979432","version":"1","preferredName":"Invasive Breast Carcinoma Nuclear Pleomorphism","preferredDefinition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women._Having nuclei with various distinct forms.","longName":"2431278v1.0:2431221v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2431278","version":"1","preferredName":"Invasive Breast Carcinoma","preferredDefinition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women. --2003","longName":"C9245","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Breast Carcinoma","conceptCode":"C9245","definition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCF1A1-FAC7-3A7D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2431221","version":"1","preferredName":"Nuclear Pleomorphism","preferredDefinition":"definition pending","longName":"C38721","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nuclear Pleomorphism","conceptCode":"C38721","definition":"Having nuclei with various distinct forms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCE306-FFB2-32FE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5927A20B-DA35-3DB4-E053-F662850ADF07","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"9/19/17 tt New DEC to incorporate 2017 CAP Nottingham Score guidelines; added CSI per Round 5 finalization task. 9/14/17 tt Draft New DEC per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5979435","version":"1","preferredName":"Nottingham Histologic Score Nuclear Pleomorphism Outcome","preferredDefinition":"A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer.  The Nottingham Score is a factor in determining the Nottingham Prognostic Index._Having nuclei with various distinct forms._The result of an action.","longName":"5979435v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"7","maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Score cannot be determined","valueDescription":"Score Indeterminate","ValueMeaning":{"publicId":"5979436","version":"1","preferredName":"Score Indeterminate","longName":"5979436","preferredDefinition":"A number or range of numeric values measuring performance, function, quality, or ability.: Cannot distinguish between two or more possible values in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indeterminate","conceptCode":"C48658","definition":"Cannot distinguish between two or more possible values in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592848D1-85A6-07D3-E053-F662850A6D47","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"592848D1-85BF-07D3-E053-F662850A6D47","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"},{"value":"No residual invasive carcinoma","valueDescription":"Negation Residual Invasive Carcinoma","ValueMeaning":{"publicId":"5979437","version":"1","preferredName":"Negation Residual Invasive Carcinoma","longName":"5979437","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Remaining or left behind.: A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Residual","conceptCode":"C37895","definition":"Remaining or left behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Invasive Carcinoma","conceptCode":"C9480","definition":"A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592848D1-85CD-07D3-E053-F662850A6D47","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"592848D1-85E6-07D3-E053-F662850A6D47","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"},{"value":"Score 3","valueDescription":"Nuclear Pleomorphism Score 3","ValueMeaning":{"publicId":"5979439","version":"1","preferredName":"Nuclear Pleomorphism Score 3","longName":"5979439","preferredDefinition":"Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and highly unusual forms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nuclear Pleomorphism Score 3","conceptCode":"C138981","definition":"Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and highly unusual forms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592848D1-861A-07D3-E053-F662850A6D47","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"592848D1-8633-07D3-E053-F662850A6D47","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"},{"value":"Score 2","valueDescription":"Nuclear Pleomorphism Score 2","ValueMeaning":{"publicId":"5979440","version":"1","preferredName":"Nuclear Pleomorphism Score 2","longName":"5979440","preferredDefinition":"Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nuclear Pleomorphism Score 2","conceptCode":"C138980","definition":"Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592848D1-863F-07D3-E053-F662850A6D47","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"592848D1-8658-07D3-E053-F662850A6D47","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"},{"value":"Score 1","valueDescription":"Nuclear Pleomorphism Score 1","ValueMeaning":{"publicId":"5979441","version":"1","preferredName":"Nuclear Pleomorphism Score 1","longName":"5979441","preferredDefinition":"Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nuclear Pleomorphism Score 1","conceptCode":"C138979","definition":"Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592848D1-8664-07D3-E053-F662850A6D47","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"592848D1-867D-07D3-E053-F662850A6D47","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"},{"value":"Only microinvasion present not graded","valueDescription":"Microinvasive Breast Carcinoma Present Negation Histologic Grade","ValueMeaning":{"publicId":"5979438","version":"1","preferredName":"Microinvasive Breast Carcinoma Present Negation Histologic Grade","longName":"5979438","preferredDefinition":"Ductal carcinoma in situ of the breast with minimal stromal invasion.  Lymph node involvement is uncommon and the prognosis is generally good.: Being or existing in a specified place or at the specified time.: An operation in which a term denies or inverts the meaning of another term or construction.: The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Microinvasive Breast Carcinoma","conceptCode":"C40374","definition":"Invasive breast carcinoma measuring 1 mm or less in size.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Present","conceptCode":"C25626","definition":"Being or existing in a specified place or at the specified time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592848D1-85F5-07D3-E053-F662850A6D47","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59285DB6-4B77-2D89-E053-F662850A5434","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5979434","version":"1","preferredName":"Nottingham Score Nuclear Pleomorphism Outcome","preferredDefinition":"A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer.  The Nottingham Score is a factor in determining the Nottingham Prognostic Index.:Having nuclei with various distinct forms.:The result of an action.","longName":"C25595:C38721:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nottingham Score","conceptCode":"C25595","definition":"A numeric representation combining three histologic reporting elements, tubule formation, nuclear pleomorphism and mitotic count, to determine the grade of breast cancer. The Nottingham Score is a factor in determining the Nottingham Prognostic Index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Nuclear Pleomorphism","conceptCode":"C38721","definition":"Having nuclei with various distinct forms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"592848D1-8579-07D3-E053-F662850A6D47","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"ONEDATA","dateModified":"2017-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"592848D1-858A-07D3-E053-F662850A6D47","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"TAYLORT","dateModified":"2019-06-13","changeDescription":"9/18/17 tt New VD supercedes 2015159 to incorporate 2017 CAP Nottingham Score guidelines; added CSI, per Round 5 finalization task.  9/14/17 tt Draft New VD per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506112","version":"1","longName":"Breast","context":"MCL","ClassificationSchemeItems":[{"publicId":"6643181","version":"1","longName":"Initial Diagnosis","context":"MCL"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"5915898","version":"1","longName":"Microscopic Pathology","context":"NCI Standards"}]},{"publicId":"7434158","version":"1","longName":"CTEP CDISC Harmonization","context":"CTEP","ClassificationSchemeItems":[{"publicId":"11422194","version":"1","longName":"CTEP CDISC Diagnosis Microscopic Pathology","context":"CTEP"}]}],"AlternateNames":[{"name":"CTEP","type":"USED_BY","context":"CTEP"},{"name":"MI_MIORRES_NCRPLEOM","type":"CTEP CDISC CDE","context":"CTEP"}],"ReferenceDocuments":[{"name":"Nuclear pleomorphism","type":"Preferred Question Text","description":"Nuclear pleomorphism","url":null,"context":"NCI Standards"},{"name":"College of American Pathologists Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast","type":"REFERENCE","description":"Version: Invasive Breast 4.0.0.0; Protocol Posting Date: June 2017","url":"http://www.cap.org/","context":"NCI Standards"},{"name":"CTEP Text 1","type":"Alternate Question Text","description":"What is the Nottingham nuclear pleomorphism score?","url":null,"context":"CTEP"},{"name":"CTEP Text 2","type":"Alternate Question Text","description":"Nottingham nuclear pleomorphism score","url":null,"context":"CTEP"}],"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5928EDCE-C249-7572-E053-F662850A41CF","latestVersionIndicator":"Yes","beginDate":"2017-09-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-09-14","modifiedBy":"CLOHNES","dateModified":"2022-10-13","changeDescription":"9/19/17 tt released CDE.  9/14/17 tt New CDE per Round 5 finalization task to incorporate 2017 CAP Nottingham Score guidelines; supercedes CDE 350.","administrativeNotes":"10/12/22 added alt name, 2 AQT, classification for CTEP CDISC Harmonization project cjl;","unresolvedIssues":null,"deletedIndicator":"No"}}